Please assess the completion status of the following clinical trial:

Trial Title: Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Adult (age ≥ 18 years)~* Admitted to the hospital of any participating center~* Confirmed SARS-CoV-2 infection with either: positive laboratory test for SARS-CoV-2\* ; or positive CT thorax diagnostic for SARS-CoV-2 infection according to the prevailing criteria~* Randomization:~  * Within 24 hours of confirmed in-hospital SARS-CoV-2 infection diagnosis OR~ * within 24 hours of hospital admission in case of pre-hospital confirmed SARS-CoV-2 infection.~    * In case there is a lack of laboratory tests for SARS-CoV-2 in the participating center of the potentially eligible patient, a positive laboratory test for SARS-CoV-2 will be no longer required. In that case, the potentially eligible patient needs to meet the prevailing criteria for the diagnosis of SARS-CoV-2 infection of that participating center, such as typical abnormalities on pulmonary CT in the setting of high clinical suspicion of SARS-CoV-2 infection.~Exclusion Criteria:~* Admitted to ICU prior to randomization~* Currently taking an ARB or angiotensin-receptor-neprilysin-inhibitor (ARNI)~* Use of other investigational drugs at the time of enrollment~* Prior reaction or intolerance to an ARB or ARNI; or severe intolerance to an ACEi, defined as angio-oedema requiring medical intervention~* Systolic blood pressure \< 105mmHg or diastolic blood pressure \<65mmHg~* Potassium greater than 5.5 mEq/L within 4 weeks of study enrollment.~* Estimated Glomerular Filtration Rate (eGFR) of \< 30ml/min/1.73 m2 within 4 weeks of study initiation~* A known history of renal artery stenosis~* AST and/or ALT \> 3 times the upper limit of normal within 4 weeks of study enrollment. In case of mild to moderate liver dysfunction valsartan dosage will be limited to a maximum of 80mg~* Severe liver dysfunction, biliary cirrhosis or cholestasis~* Severe volume depletion or severe acute kidney injury that, in the opinion of the investigator, would preclude administration of valsartan~* Concurrent treatment with Aliskiren~* Inability to obtain informed consent~* Pregnancy or breastfeeding~* In females of childbearing age, unwillingness to use birth control or to be sexually abstinent for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active treatment arm (Type: EXPERIMENTAL): Valsartan at a dosage and frequency titrated to blood pressure with 80mg or 160mg tablets up to a maximum dose of 160mg b.i.d.
- Placebo arm (Type: PLACEBO_COMPARATOR): Matching 80mg or 160mg placebo tablets at a dosage and frequency titrated to systolic blood pressure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues